Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04264845 · ClinicalTrials.gov registry record
Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure
A clinical trial of Heart Failure, sponsored by Intermountain Health Care.
- Active
- Registry status
- 3,640
- Enrollment target
- 1
- Study location
NCT04264845: Active study of Heart Failure, sponsored by Intermountain Health Care.
NCT04264845 is a study of Heart Failure that is active but no longer recruiting, run by Intermountain Health Care. The registered enrollment target is 3,640 participants, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (78% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04264845, a study of Heart Failure, is active but no longer recruiting, sponsored by Intermountain Health Care.
- ACTIVE NOT RECRUITING
- Registry status
- 3,640 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, observational, open study that will utilize the following tools: survey/questionnaire research, interviews, and focus groups, and secondary/archival data analysis. In addition, a subset of selected subjects will be asked to provide blood samples to examine the biologic determinants of patient health status in heart failure (HF). This will help us understand better the biomarkers or genetic factors that may cause differences in patient quality of life.
Primary Outcome
It is believed that data entry requirement below 10 minutes is conducive to patient participation and will not interfere with clinic flow. This will me monitored throughout the trial.
Conditions Studied
Interventions
- OTHER Provider Focus
- OTHER Patient Interview
- OTHER PROs/Clinical Data Integration
Study Locations (1)
Utah
- Intermountain Heart Institute - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,640 participants |
| Start Date | 2019-12-01 |
| Est. Completion | 2026-03 |
What the registry record for NCT04264845 still lists
NCT04264845 is an observational study that tracks outcomes without assigning an intervention. Its 3,640 participants enrollment target places it among the larger protocols in the corpus, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (78% higher).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Provider Focus is the first listed.
NCT04264845 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04264845 about?
NCT04264845 is a clinical study titled "Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure". This is a prospective, observational, open study that will utilize the following tools: survey/questionnaire research, interviews, and focus groups, and secondary/archival data analysis. In addition, a subset of selected subjects will be asked to provide blood samples to examine the biologic determi...
What is the current status of trial NCT04264845?
This trial is currently active not recruiting. The enrollment target is 3,640 participants. The study started on 2019-12-01. Estimated completion is 2026-03.
What conditions does trial NCT04264845 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT04264845?
The interventions under investigation include: Provider Focus (OTHER), Patient Interview (OTHER), PROs/Clinical Data Integration (OTHER).
Who is sponsoring clinical trial NCT04264845?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04264845 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04264845's enrollment target sits among peer trials
3,640 32nd of 397 higher than 366 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
- NCT07249398 · 3,650 participants · NA
Influence of Social Media Ads on Food Choice - Master Protocol
- NCT06354920 · 3,624 participants · NA
M-Well Bonding Bundle to Improve Patient-Physician Relationships
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI